{"id":146694,"date":"2022-09-20T01:23:55","date_gmt":"2022-09-20T06:23:55","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/09\/unity-biotechnology-completes-enrollment-in-phase-2-envision-study-of-ubx1325-in-wet-age-related-macular-degeneration"},"modified":"2022-09-20T01:23:55","modified_gmt":"2022-09-20T06:23:55","slug":"unity-biotechnology-completes-enrollment-in-phase-2-envision-study-of-ubx1325-in-wet-age-related-macular-degeneration","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/09\/unity-biotechnology-completes-enrollment-in-phase-2-envision-study-of-ubx1325-in-wet-age-related-macular-degeneration","title":{"rendered":"UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration"},"content":{"rendered":"<p><a class=\"blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/unity-biotechnology-completes-enrollment-in-phase-2-envision-study-of-ubx1325-in-wet-age-related-macular-degeneration2.jpg\"><\/a><\/p>\n<p><em>Enrollment of 51 patients exceeds target by ~10% due to high interest in the study<\/em><\/p>\n<p><center><em>16-week data anticipated in Q1 2023 and 24-week data anticipated in Q2 2023<\/em><\/center><\/p>\n<p>SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) \u2014 UNITY Biotechnology, Inc. (\u201cUNITY\u201d) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has completed enrollment for the ENVISION study, its Phase 2 clinical trial of UBX1325 in patients with wet age-related macular degeneration (AMD). This is an active comparator study, examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Enrollment of 51 patients exceeds target by ~10% due to high interest in the study 16-week data anticipated in Q1 2023 and 24-week data anticipated in Q2 2023 SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) \u2014 UNITY Biotechnology, Inc. (\u201cUNITY\u201d) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases [\u2026]<\/p>\n","protected":false},"author":556,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269],"tags":[],"class_list":["post-146694","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/146694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=146694"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/146694\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=146694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=146694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=146694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}